Results 191 to 200 of about 84,248 (219)

Onasemnogene Abeparvovec in Type I Spinal Muscular Atrophy: 24‐Month Follow‐Up From the Italian Registry

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Onasemnogene abeparvovec (OA) is an AAV9‐based gene therapy for spinal muscular atrophy type I (SMA I). Real‐world outcomes show increased response variability compared to clinical trials, and follow‐up data beyond 12–18 months are limited.
Marika Pane   +43 more
wiley   +1 more source

A hybrid experimental-numerical framework for prestressed concrete bridge model validation and sensor placement optimization: a case study. [PDF]

open access: yesSci Rep
Jayasinghe SC   +8 more
europepmc   +1 more source
Some of the next articles are maybe not open access.

Related searches:

Cross-modal attention for multi-modal image registration

Medical Image Analysis, 2022
Hanqing Chao, Bj Wood, Hengtao Guo
exaly  

Home - About - Disclaimer - Privacy